

ABSTRACT

A novel polypeptide drug carrier is provided wherein polypeptides containing glutamic acid and aspartic acid, or glutamic acid/alanine, or glutamic acid/asparagine, or glutamic acid/glutamine, or glutamic acid/glycine, are conjugated to drugs in order to improve the solubility of the drugs and/or their therapeutic efficacy *in vivo*. An illustrative example involves the conjugation of paclitaxel to a poly(glutamic acid/aspartic acid) polypeptide and its efficacy in the treatment of prostate cancer *in vivo*.

5